https://ros1signal.com/index.p....hp/term-localization
A total of 42 patients had been matched based on tumefaction stage (T1-2-3, N0, M, number of tumors, R0 resection, no 90-day death, and follow-up. Major endpoints had been disease-free success (DFS) and overall success (OS). Disease-free success prices at 1-, 3-, and 5-year had been 71.4%, 57.1%, 35.7% for transitional HCC-CC customers; 85.7%, 40.4%, 10.1% for HCC clients; 85.1%, 34.0%, 22.7% for MFCCC clients (5-year DFS HCC-CC vs. HCC, p = 0.575; HCC-CC vs. MFCCC, p =
Like
Comment
Share
